Kit for radiopharmaceutical preparation Tektrotyd receives Marketing Authorisation in the Nordics
Tektrotyd

Kit for radiopharmaceutical preparation Tektrotyd receives Marketing Authorisation in the Nordics

SAM Nordic are happy to announce that the kit TEKTROTYD has received Marketing Authorisation in Sweden, Finland, Norway and Denmark this day.

99mTc-Tektrotyd is a radiopharmaceutical indicated for diagnostics of pathological lesions in which somatostatin receptors are overexpressed (particularly subtype 2 and, to a lesser extent, subtypes 3 and 5) and which may be imaged by the labelled ligand.

In particular, these are:

  • Gastro-entero-pancreatic neuroendocrine tumours (GEP-NET);
  • pituitary adenomas;
  • tumours originating in a sympathetic system; pheochromocytoma, paraganglioma, neuroblastoma, ganglioneurinoma etc.;
  • medullary thyroid carcinoma;
  • the preparation may be potentially useful in the case of other tumours expressing somatostatin receptors of various intensity. Other tumours which may overexpress somatostatin receptors: breast cancer, melanoma, lymphomas, prostate cancer, NSCLC, sarcoma, renal cell carcinoma, differentiated thyroid carcinoma, astrocytoma according to WHO I-IV (including glioblastoma multiforme G-M), meningiomas, ovarian cancer.